Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells

References

• Arnold KM, Flynn NJ, Raben A, Romak L, Yu Y, Dicker AP, Mourtada F, Sims-Mourtada J. 2018. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Cancer Growth Metastasis. 11:1179064418761639.
   Web of Science ®Google Scholar
• Arnold KM, Opdenaker LM, Flynn D, Sims-Mourtada J. 2015. Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis. 8:1–13.
   PubMed Web of Science ®Google Scholar
• Banerjee K, Resat H. 2016. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 138(11):2570–2578.
   PubMed Web of Science ®Google Scholar
• Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. 2004. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 10(21):7157–7162.
   PubMed Web of Science ®Google Scholar
• Bharadwaj U, Eckols TK, Xu X, Kasembeli MM, Chen Y, Adachi M, Song Y, Mo Q, Lai SY, Tweardy DJ. 2016. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 7:26307–26330.
   PubMedGoogle Scholar
• Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, Lin J, Li PK. 2008. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett. 18(1):391–395.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. 2016. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 13(11):674–690.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Trummell HQ, Willey CD, Plants BA, Raisch KP. 2009. Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. Radiother Oncol. 92(3):339–344.
   PubMed Web of Science ®Google Scholar
• Canino C, Luo Y, Marcato P, Blandino G, Pass HI, Cioce M. 2015. A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. Oncotarget. 6(14):12637–12653.
   PubMedGoogle Scholar
• Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, et al. 2009. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69(4):1302–1313.
   PubMed Web of Science ®Google Scholar
• Cho YA, Sung MK, Yeon JY, Ro J, Kim J. 2013. Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. Cancer Res Treat. 45(3):210–219.
   PubMed Web of Science ®Google Scholar
• Chung SS, Giehl N, Wu Y, Vadgama JV. 2014. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 44(2):403–411.
   PubMed Web of Science ®Google Scholar
• Croker AK, Allan AL. 2012. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res Treat. 133(1):75–87.
   PubMed Web of Science ®Google Scholar
• Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. 2009. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 13(8b):2236–2252.
   PubMed Web of Science ®Google Scholar
• Croker AK, Rodriguez-Torres M, Xia Y, Pardhan S, Leong HS, Lewis JD, Allan AL. 2017. Differential functional roles of ALDH1A1 and ALDH1A3 in mediating metastatic behavior and therapy resistance of human breast cancer cells. Int J Mol Sci. 18:pii: E2039.
   Web of Science ®Google Scholar
• Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R, Haura EB. 2005. Stat3 regulates genes common to both wound healing and cancer. Oncogene. 24(21):3397–3408.
   PubMed Web of Science ®Google Scholar
• Dethlefsen C, Hojfeldt G, Hojman P. 2013. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 138(3):657–664.
   PubMed Web of Science ®Google Scholar
• Di Maggio FM, Minafra L, Forte GI, Cammarata FP, Lio D, Messa C, Gilardi MC, Bravata V. 2015. Portrait of inflammatory response to ionizing radiation treatment. J Inflamm. 12(1):14.
   Google Scholar
• Do DV, Ueda J, Messerschmidt DM, Lorthongpanich C, Zhou Y, Feng B, Guo G, Lin PJ, Hossain MZ, Zhang W, et al. 2013. A genetic and developmental pathway from STAT3 to the OCT4-NANOG circuit is essential for maintenance of ICM lineages in vivo. Genes Dev. 27(12):1378–1390.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. 2010. Triple-negative breast cancer. N Engl J Med. 363(20):1938–1948.
   PubMed Web of Science ®Google Scholar
• Gao L, Li F, Dong B, Zhang J, Rao Y, Cong Y, Mao B, Chen X. 2010. Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells. Int J Radiat Oncol Biol Phys. 77(4):1223–1231.
   PubMed Web of Science ®Google Scholar
• Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM. 2013. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem. 288(36):26167–26176.
   PubMed Web of Science ®Google Scholar
• Ghisolfi L, Keates AC, Hu X, Lee DK, Li CJ. 2012. Ionizing radiation induces stemness in cancer cells. PLoS One. 7(8):e43628.
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1(5):555–567.
   PubMed Web of Science ®Google Scholar
• Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, et al. 2010. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 120(2):485–497.
   PubMed Web of Science ®Google Scholar
• Goumas FA, Holmer R, Egberts JH, Gontarewicz A, Heneweer C, Geisen U, Hauser C, Mende MM, Legler K, Rocken C, et al. 2015. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int J Cancer. 137(5):1035–1046.
   PubMed Web of Science ®Google Scholar
• Guo S, Liu M, Gonzalez-Perez RR. 2011. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta. 1815:197–213.
   PubMed Web of Science ®Google Scholar
• Harrison C, Vannucchi AM. 2012. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol. 3(6):341–354.
   PubMedGoogle Scholar
• Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, et al. 2015. Randomized, double-blind, phase ii study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 33(34):4039–4047.
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Hirsch HA, Wang G, Struhl K. 2011. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA. 108(4):1397–1402.
   PubMed Web of Science ®Google Scholar
• Jones LM, Broz ML, Ranger JJ, Ozcelik J, Ahn R, Zuo D, Ursini-Siegel J, Hallett MT, Krummel M, Muller WJ. 2016. STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. Cancer Res. 76(6):1416–1428.
   PubMed Web of Science ®Google Scholar
• Kida K, Ishikawa T, Yamada A, Shimada K, Narui K, Sugae S, Shimizu D, Tanabe M, Sasaki T, Ichikawa Y, et al. 2016. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype. Breast Cancer Res Treat. 156(2):261–269.
   PubMed Web of Science ®Google Scholar
• Kim RK, Kaushik N, Suh Y, Yoo KC, Cui YH, Kim MJ, Lee HJ, Kim IG, Lee SJ. 2016. Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer. Oncotarget. 7(33):53430–53442.
   PubMedGoogle Scholar
• Kim SY, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT, Lee YJ. 2013. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal. 25(4):961–969.
   PubMed Web of Science ®Google Scholar
• Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. 2012. Radiation-induced reprogramming of breast cancer cells. Stem Cells. 30(5):833–844.
   PubMed Web of Science ®Google Scholar
• Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. 2011. STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol. 344:41–59.
   PubMed Web of Science ®Google Scholar
• Lewis KM, Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Fridley C, Siller R, Tweardy DJ. 2015. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lung Cancer. 90(2):182–190.
   PubMed Web of Science ®Google Scholar
• Lin L, Hutzen B, Lee HF, Peng Z, Wang W, Zhao C, Lin HJ, Sun D, Li PK, Li C, et al. 2013. Evaluation of STAT3 signaling in ALDH + and ALDH+/CD44+/CD24- subpopulations of breast cancer cells. PLoS One. 8(12):e82821.
   PubMed Web of Science ®Google Scholar
• Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM. 2015. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 62(10):1717–1724.
   PubMed Web of Science ®Google Scholar
• Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, et al. 2011. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 29(1):32–45.
   PubMed Web of Science ®Google Scholar
• Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, et al. 2011. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest. 121(7):2723–2735.
   PubMed Web of Science ®Google Scholar
• Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, Pandya D, Lu Y, Mills GB, Aster JC, et al. 2010. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci USA. 107(11):5012–5017.
   PubMed Web of Science ®Google Scholar
• Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, Heo DS, Yuasa M, Yanagihara Y, Bang YJ. 2015. Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat. 47(4):607–615.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Ueno H, Ikeda M, Mitsunaga S, Ozaka M, Ishii H, Yokosuka O, Ooka Y, Yoshimoto R, Yanagihara Y, et al. 2015. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res. 45(13):1283–1291.
   PubMed Web of Science ®Google Scholar
• Opdenaker LM, Modarai SR, Boman BM. 2015. The proportion of ALDEFLUOR-positive cancer stem cells changes with cell culture density due to the expression of different ALDH isoforms. Cancer Stud Mol Med. 2(2):87–95.
   PubMedGoogle Scholar
• Phillips TM, McBride WH, Pajonk F. 2006. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 98(24):1777–1785.
   PubMedGoogle Scholar
• Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, et al. 2013. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat. 142(2):237–255.
   PubMed Web of Science ®Google Scholar
• Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. 2011. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 117(21):5701–5709.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature. 414(6859):105–111.
   PubMed Web of Science ®Google Scholar
• Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, Alvarez MJ, Kendsersky ND, Pelz CR, Johnson-Camacho K, et al. 2018. Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun. 9(1):3815.
   PubMed Web of Science ®Google Scholar
• Rycaj K, Tang DG. 2014. Cancer stem cells and radioresistance. Int J Radiat Biol. 90(8):615–621.
   PubMed Web of Science ®Google Scholar
• Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, et al. 2007. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 117(12):3988–4002.
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Nguyen GH, Bowman ED, Mathe EA, Yuen ST, Hawkes JE, Croce CM, Leung SY, Harris CC. 2009. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res. 15(18):5878–5887.
   PubMed Web of Science ®Google Scholar
• Schust J, Sperl B, Hollis A, Mayer TU, Berg T. 2006. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 13(11):1235–1242.
   PubMed Web of Science ®Google Scholar
• Sethi N, Dai X, Winter CG, Kang Y. 2011. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2):192–205.
   PubMed Web of Science ®Google Scholar
• Su YL, Banerjee S, White SV, Kortylewski M. 2018. STAT3 in tumor-associated myeloid cells: multitasking to disrupt immunity. Int J Mol Sci. 19:pii: E1803.
   Web of Science ®Google Scholar
• Thomas ML, de Antueno R, Coyle KM, Sultan M, Cruickshank BM, Giacomantonio MA, Giacomantonio CA, Duncan R, Marcato P. 2016. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3. Mol Oncol. 10(9):1485–1496.
   PubMed Web of Science ®Google Scholar
• Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, Bullock A, Rock E, Elekes A, Lin C, et al. 2018. A first-in-human phase i study of OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers. Oncologist. 23(6):658–e672.
   PubMed Web of Science ®Google Scholar
• Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y, et al. 2018. JAK/STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 27(1):136–150. e135.
   PubMed Web of Science ®Google Scholar
• Wei W, Tweardy DJ, Zhang M, Zhang X, Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM, et al. 2014. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 32(10):2571–2582.
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A. 2016. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog. 55(5):832–841.
   PubMed Web of Science ®Google Scholar
• Zhang M, Shoeb M, Goswamy J, Liu P, Xiao TL, Hogan D, Campbell GA, Ansari NH. 2010. Overexpression of aldehyde dehydrogenase 1A1 reduces oxidation-induced toxicity in SH-SY5Y neuroblastoma cells. J Neurosci Res. 88:686–694.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao X, Shao S, Zuo X, Ning Q, Luo M, Gu S, Zhao X. 2015. Notch1 induces epithelial-mesenchymal transition and the cancer stem cell phenotype in breast cancer cells and STAT3 plays a key role. Int J Oncol. 46(3):1141–1148.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Lin Y, Shen S, Zhou Y, Mao F, Guan J, Sun Q. 2013. Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse. Cancer Cell Int. 13(1):60.
   PubMed Web of Science ®Google Scholar